Byetta [package insert]. San Diego, Calif: Amylin Pharmaceuticals; 2006.
2.
American Diabetes Association. Standards of medical care in diabetes—2006. Diabetes Care.2006;29(suppl 1): S4-S42.
3.
Del Prato S, Felton A, Munro N, Nesto R, Zimmet P, Zinman B, for the Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract.2005; 59: 1345-1355.
4.
Siminerio L, Zgibor J, Solano FX Jr.Implementing the chronic care model for improvements in diabetes practice and outcomes in primary care: the University of Pittsburgh Medical Center experience. Clin Diabetes.2004;22: 54-58.
5.
Bayless M, Martin C.The team approach to intensive diabetes management. Diabetes Spectrum.1998;11: 33-37.
6.
Cryer PE, Davis SN, Shamoon H.Hypoglycemia in diabetes. Diabetes Care.2003;26: 1902-1912.
7.
Kitabchi AE, Umpierrez GE, Murphy MB, et al.Management of hyperglycemic crises in patients with diabetes. Diabetes Care.2001;24: 131-153.
8.
Cusick M, Meleth AD, Agrón E, et al.Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes. Diabetes Care.2005;28: 617-625.
9.
Rubin RR.Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med.2005;118: 27S-34S.
10.
Rosen AB.Indications for and utilization of ACE inhibitors in older individuals with diabetes: findings from the National Health and Nutrition Examination Survey 1999 to 2002. J Gen Intern Med.2006;21: 315-319.
